Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph A Paladino

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Pharmacotherapy|December 9, 2004
Economics of antibiotic use policiesJoseph A Paladino
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 31, 2002
Linezolid: an oxazolidinone antimicrobial agentJoseph A Paladino
Pharmacoeconomics|June 17, 2010
Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision modelJack Brown, Joseph A Paladino
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2010
Outpatient parenteral antimicrobial therapy todayJoseph A Paladino, Donald Poretz
The Journal of Antimicrobial Chemotherapy|April 19, 2003
Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parametersJoseph A Paladino, Wendy A Callen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 17, 2008
The economics of Clostridium difficile-associated disease for providers and payersJoseph A Paladino, Jerome J Schentag
Pharmacoeconomics|February 20, 2008
Meandering down the road to transparencyChristopher I Carswell, Joseph A Paladino
Pharmacoeconomics|July 11, 2013
Protease inhibitors for hepatitis C: economic implicationsStuart J Turner, Jack Brown, Joseph A Paladino
International Journal of Antimicrobial Agents|March 4, 2008
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infectionsPeggy S McKinnon, Joseph A Paladino, Jerome J Schentag
Pharmacoeconomics|May 9, 2014
A review of the economics of treating Clostridium difficile infectionKari A Mergenhagen, Amy L Wojciechowski, Joseph A Paladino
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Pharmacotherapy|December 9, 2004
Economics of antibiotic use policiesJoseph A Paladino
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|December 31, 2002
Linezolid: an oxazolidinone antimicrobial agentJoseph A Paladino
Pharmacoeconomics|June 17, 2010
Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision modelJack Brown, Joseph A Paladino
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 25, 2010
Outpatient parenteral antimicrobial therapy todayJoseph A Paladino, Donald Poretz
The Journal of Antimicrobial Chemotherapy|April 19, 2003
Fluoroquinolone benchmarking in relation to pharmacokinetic and pharmacodynamic parametersJoseph A Paladino, Wendy A Callen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 17, 2008
The economics of Clostridium difficile-associated disease for providers and payersJoseph A Paladino, Jerome J Schentag
Pharmacoeconomics|February 20, 2008
Meandering down the road to transparencyChristopher I Carswell, Joseph A Paladino
Pharmacoeconomics|July 11, 2013
Protease inhibitors for hepatitis C: economic implicationsStuart J Turner, Jack Brown, Joseph A Paladino
International Journal of Antimicrobial Agents|March 4, 2008
Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infectionsPeggy S McKinnon, Joseph A Paladino, Jerome J Schentag
Pharmacoeconomics|May 9, 2014
A review of the economics of treating Clostridium difficile infectionKari A Mergenhagen, Amy L Wojciechowski, Joseph A Paladino
Pageof 3